CSF2 and rheumatoid arthritis: Given the importance of GM-CSF during CHIKV infection, its potential as a future CHIKV therapeutic target is further justified by clinical trials evaluating GM-CSF blockade in RA patients (Burmester et al, 2017; Taylor et al, 2019).